Article

DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: a meta-analysis and systematic review

2023-05-28

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Purpose</h4> The addition of PARP inhibitors to chemotherapy has been assessed in ∼80 clinical trials across multiple malignancies, on the premise that PARP inhibitors will increase chemotherapy effectiveness regardless of whether cancers have underlying disruption of DNA repair pathways. Consequently, the majority of combination therapy trials have been performed on patients without biomarke...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f541feda-d69b-5db3-9bf3-e1242792905a
DOI: 10.1101/2023.05.24.23290442

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: a meta-analysis and systematic reviewDOI 10.1101/2023.05.24.23290442Read

Update on Combination Strategies of PARP InhibitorsSemantic proximity Read

PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant CancersSemantic proximity Read

Predictive biomarkers for cancer therapy with PARP inhibitors.Semantic proximity Read

Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trialsSemantic proximity Read

Role of Biomarkers in the Development of PARP InhibitorsSemantic proximity Read

A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.Semantic proximity Read

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read

Efficacy and safety analysis of PARP inhibitors combined with drugs for primary and relapsed ovarian cancer: A meta-analysis of randomized controlled trialsSemantic proximity Read

Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Cancer: Systematic Review and Network Meta-AnalysisSemantic proximity Read

Therapeutic targeting and patient selection for cancers with homologous recombination defects.Semantic proximity Read

Strategies for the prevention or reversal of PARP inhibitor resistance.Semantic proximity Read

Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspectiveSemantic proximity Read